We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

PRECOS Appoints Dr Martin Page as Scientific Consultant

PRECOS Appoints Dr Martin Page as Scientific Consultant

PRECOS Appoints Dr Martin Page as Scientific Consultant

PRECOS Appoints Dr Martin Page as Scientific Consultant

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "PRECOS Appoints Dr Martin Page as Scientific Consultant"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Preclinical Oncology Services Limited (PRECOS) has announced the appointment of Dr Martin Page as scientific consultant.

Dr Page brings over 28 years’ experience of oncology R&D leadership gained from the pharmaceutical and biotechnology sectors across UK, Europe and USA.

His extensive therapeutic experience and industry knowledge will contribute to the company’s expert delivery of innovative patient relevant models for oncology research.

Dr Page has led multiple teams discovering novel targeted small molecule and MAb anti-cancer agents which have entered clinical trials.

Prior to this new role, he was Vice President, Head of Global Oncology Research for Johnson & Johnson Pharmaceuticals, responsible for laboratories in Belgium and USA.

Dr Neil Rotherham, chairman of the PRECOS board comments, “We are delighted to welcome Martin to our team of visionary scientists. Dr Page’s expertise will be invaluable in PRECOS’ continued success as a trusted and preferred partner for some of the world’s leading oncology research companies.”

Previously Dr Page has held senior positions as Oncology Therapeutic Area Head/Europe for Glaxo-Wellcome and Senior Director positions in the biotechnology companies Oxford GlycoSciences and Oncogene Sciences Inc.

He will support PRECOS to continue to advance its world-leading work in the evaluation of potential therapeutic agents, regimens and basic research into deriving the most relevant in vitro and in vivo screening models.

“I am extremely excited to work alongside the PRECOS team of expert scientists who are leading the way in providing robust models to enable testing of the next generation of oncology drug candidates,” said Dr Page.

Dr Page continued, “PRECOS translates its expertise in cancer drug development to enable the development of medicines with real patient benefits and my appointment reinforces the ambition and potential of PRECOS to contribute in a significant way to the growing cancer therapy market.”

Dr Martin Page will be attending the AACR conference, Chicago, March 31st - April 4th 2012, booth #4306, where PRECOS will be showcasing several new platforms for pre-clinical oncology research.